SRRK Average Annual Return Since 2018
Growth of $10,000.00
Without Dividends Reinvested Into SRRK


Also see:
SRRK stock yearly return 2019
SRRK stock yearly return 2020
SRRK stock yearly return 2021
SRRK stock yearly return 2022
SRRK stock yearly return 2023
SRRK YTD return
Compare SRRK average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Start date: 05/29/2018
End date: 03/27/2024
Start price/share: $16.12
End price/share: $15.45
Dividends collected/share: $0.00
Total return: -4.16%
SRRK Average Annual Return: -0.73%
Starting investment: $10,000.00
Ending investment: $9,581.64
Years: 5.83


SRRK average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Scholar Rock is a biopharmaceutical company focused on the discovery and development of medicines for the treatment of serious diseases. Co. has progressed the development of: Apitegromab, an inhibitor of the activation of latent myostatin for the treatment of spinal muscular atrophy; SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies; selective inhibitors of the activation of transforming growth factor beta for the treatment of fibrotic diseases; and additional discovery and early preclinical programs related to the selective modulation of growth factor signaling. The SRRK average annual return since 2018 is shown above.

The Average Annual Return on the SRRK average annual return since 2018 page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether SRRK average annual return since 2018 or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the SRRK average annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes

Email EnvelopeFree SRRK Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Scholar Rock Holding (SRRK) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

SRTS Average Annual Return
SSKN Average Annual Return
STAA Average Annual Return
STE Average Annual Return
STIM Average Annual Return
STOK Average Annual Return
STRO Average Annual Return
STRR Average Annual Return
STSS Average Annual Return
STTK Average Annual Return
More Healthcare companies »

 

SRRK Average Annual Return Since 2018 | www.AverageAnnualReturn.com | Copyright © 2021 - 2024, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.